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1Université Victor Segalen Bordeaux 2, Bordeaux cedex, 
France; 2J2C Santé, Mérignac, France
OBJECTIVE: Enoxaparin is a low-molecular-weight hep-
arin widely used in the prophylaxis and treatment of
venous thromboembolism. This study critically reviews
recent literature to determine the clinical conditions for
which enoxaparin can be considered as a gold standard
treatment from both outcome and cost standpoints.
METHODS: A Medline and current contents search for
published pharmacoeconomic evaluations, from 1980 to
present, was conducted. Abstracts were excluded. A large
range of cost-effectiveness and cost-utility analyses were
available, mainly comparing enoxaparin with unfraction-
ated heparin (UFH) and warfarin, and taking into ac-
count the different dosage regimens (30 mg, 40 mg once
or twice daily) currently recommended for durations
ranging from 5 days to 3 months. Efficiency was often in-
vestigated on the basis of decision trees setting out clini-
cal alternatives and probable events: deep vein thrombo-
sis (DVT); pulmonary embolism (PE); major bleed; death.
Clinical outcome data were extracted from selected ran-
domized, controlled trials or meta-analyses. In most
cases, direct costs were only estimated.
RESULTS: Enoxaparin was shown to be more efficient than
UFH in the treatment of acute DVT in the hospital setting
than warfarin for the short-term prophylaxis of throm-
boembolism in inpatients undergoing knee or hip replace-
ment. Long-term enoxaparin therapy for outpatients was
associated with better cost-effectiveness or cost-utility ratios
than enoxaparin treatment in elective hip surgery. More-
over, enoxaparin emerged as a dominant strategy versus
UFH therapy, yielding overall cost savings in outpatient ex-
tended prophylaxis for hip surgery; in general surgery and
in outpatient treatment of acute proximal DVT.
CONCLUSION: There is now strong clinical and economic
evidence that enoxaparin may be more effective than war-
farin and UFH, perhaps safer than UFH, while reducing
short-term costs of thromboembolic events but also the sub-
stantial long-term costs of post-thrombotic complications.
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ASSESSING THE IMPACT OF HYPERLIPIDEMIA 
TREATMENT WITH PRAVASTATIN AND 
SIMVASTATIN IN A LARGE 
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OBJECTIVE: The purpose of this study is to evaluate if a
sample county-hospital population has achieved target
cholesterol values, per National Cholesterol Education
Program (NCEP) guidelines while on pravastatin or simv-
astatin therapy.
METHODS: A chart review of patients from eleven
health-care facilities within the county was obtained for
evaluation of current total cholesterol (TC), low density
lipoprotein (LDL), high density lipoprotein (HDL) and
triglyceride levels. The inclusion criteria consisted of pa-
tients who had undergone HMG-CoA reductase inhibitor
therapy for at least six months. They were retrospectively
evaluated to determine impact on lipid profile. Data col-
lection included demographics such as, gender, race, and
risk factors, in addition to the standard lipid profile.
RESULTS: Results are being reported for the initial 120
patients evaluated. On the average, post-treatment TC
and LDL levels are 219 mg/dl and 136 mg/dl, respec-
tively, in the sample population. Results indicate that
only about 36% of the patients have reached target TC
and LDL levels per NCEP guidelines while 64% of the
patients were above target levels. Of the two agents eval-
uated, 75% of the patients on pravastatin reached treat-
ment goals while only 26% of the patients on simvastatin
reached treatment goals. African-Americans, after treat-
ment, had the highest TC and LDL values. Overall, the
patients had an average of three risk factors.
CONCLUSION: The preliminary study results indicate
that a high percentage of county hospital patients have
TC values  200 mg/dl and LDL values 130 mg/dl,
even after therapy with an HMG-CoA reductase inhibi-
tor. Patients with more than two risk factors and a LDL
level greater than 130 mg/dl must be targeted for more
aggressive pharmacotherapeutic management and be en-
couraged to make necessary lifestyle changes. Additional
studies are needed to determine the effect of different
pharmacological agents and ethnic influences on out-
come.
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University of Liverpool, Liverpool, UK
OBJECTIVES: Non-compliance is a major problem in
clinical practice and often leads to sub-optimal therapeu-
tic response. This is particularly evident when effective
treatment is available for a chronic, asymptomatic dis-
ease. In the present study, an evaluation of the impact of
non-compliance on the clinical efficacy of antihyperlipi-
daemic drugs is made.
METHODS: An electronic search of the literature was
conducted in order to identify trials and other reports
that presented compliance data and clinical endpoints
(reduction in LDL cholesterol). Assuming a class effect
for the actions of HMG-CoA reductase inhibitors (stat-
ins), estimates of cost-effectiveness (cost per percentage
reduction in LDL cholesterol) were made for individual
drugs at the different compliance rates.
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RESULTS: Non-compliance is a significant problem in
managing hypercholesterolaemia. Discontinuation rates
for statins in normal practice average 30% after six
months. This results in a significant loss of therapeutic re-
sponse. In the EXCEL study (lovastatin), a 41.3% reduc-
tion in LDL cholesterol was observed in those patients
who reported taking all their tablets. This compared with
a 26.6% reduction in those taking 80% of their tablets. In
a primary-care setting, the discontinuation rate for prava-
statin was 24% after two years. The reduction in LDL
cholesterol was 6% compared to 26% in those continuing
treatment. This results in a change in cost-effectiveness
from £376 to £1754 per % LDL reduction per year.
CONCLUSIONS: Noncompliance is an important factor
when assessing a drug’s effectiveness in clinical practice.
Tables comparing the cost-effectiveness of statins are of-
ten found in the medical literature, but rarely do they ac-
count for noncompliance. The present study illustrates
the need to account for the impact of noncompliance in
pharmacoeconomic evaluations.
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OBJECTIVE: Patients with hypertension are often non-
compliant with their medication. A study was conducted
in a usual clinical practice setting in patients with essen-
tial hypertension to improve medication compliance by
modifying behavior.
METHODS: The trial was designed as a randomized,
multi-center, open-label, two-arm study in patients with
essential hypertension. Four thousand eight hundred
sixty four patients recruited from general practice settings
were randomized to receive the angiotensin-receptor
blocker irbesartan with (intervention group) or without
(non-intervention group) a behavioral modification pro-
gram (Avapromise), which was based on a model of
change, and followed up for 12 months. Randomization
to Avapromise was done by site (recruiting physicians’
office) such that all the patients within one site were ran-
domized to the same treatment regimen to avoid contam-
ination and to minimize investigator bias. Patients were
sub-grouped based on their stage of change in the behav-
ioral change continuum, and the intervention was tai-
lored to address the needs of the particular sub-group.
Primary efficacy measure was rate and time to discontin-
uation with irbesartan.
RESULTS: At the end of the study the total number of
patient discontinuations was 1240 (25% of 4864). Of
these, 611 (25.4%, 95% CI: 23.7–27.2) occurred in the
intervention group and 629 (25.5%, 95% CI: 23.8–27.3)
occurred in the non-intervention group. This resulted in a
difference of 0.1% (2.6 to 2.3) between the two groups
(p  0.94). The time to discontinuation was not different
between the groups (p  0.87). The extrapolated rate of
discontinuation estimated from the Kaplan-Meier curve
was also not different between the groups (intervention:
23.1%, 95% CI: 21.3–24.8; non-intervention: 23.5%,
95% CI: 21.8–25.3).
CONCLUSION: This behavioral modification interven-
tion based on a model of change was not effective in in-
creasing compliance rates in patients with essential hy-
pertension in this setting.
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OBJECTIVE: The development of low-molecular-weight
heparins (LMWHs) as an antithrombin therapy for the
management of acute coronary syndromes was prompted
by the shortcomings of unfractionated heparin (UFH), the
standard therapy. LMWHs, and especially the most widely
used enoxaparin, offer the advantages of a stable and pre-
dictable anticoagulant response to a given dose, eliminat-
ing the need for haematologic monitoring, and much sim-
pler administration via the subcutaneous route. However,
enoxaparin should achieve improved clinical effectiveness
and demonstrate economic attractiveness. The present re-
view is an appraisal of the relative costs and benefits of
enoxaparin versus UFH in acute cardiology.
METHODS: A growing number of papers have been ad-
dressing these questions during the last five years. Most
of them are based on two worldwide multi-center, dou-
ble-blind, randomized controlled trials, TIMI 11B and
ESSENCE, involving patients with unstable angina/
non-Q wave myocardial infarction. Efficiency was evalu-
ated prospectively over the first 30 days of follow-up and
retrospectively after one year of follow up, using cost-ef-
fectiveness approach. Only direct costs were measured.
RESULTS: Enoxaparin was shown to be a dominant
strategy. It clearly improved efficacy and tolerability ver-
sus UFH, providing an absolute risk reduction of death,
myocardial infarction and recurrent angina of 3.7% to
3.5% at more or less short term. Average cost per patient
was significantly lower due to reduced frequency of diag-
nostic catheterization, revascularization procedures, an-
giography, coronary angioplasty and shorter length of
hospital stay over the first 30 days. Cost reduction arose,
on the long term, from less rehospitalizations and revas-
cularizations. Moreover, those reductions were probably
underestimated as indirect costs were not considered.
